Abstract
The effects of fluvastatin therapy on parameters of coagulation and fibrinolysis were evaluated in patients with diabetic dyslipidemia in a randomized, placebo-controlled study. Fluvastatin therapy was associated with a small reduction in factor VII coagulant activity, von Willebrand factor, and in plasminogen activator inhibitor 1 and tissue plasminogen activator antigens, but the effects of fluvastatin on hemostatic factors were much less marked than its effects on plasma lipids.
Publication types
-
Clinical Trial
-
Randomized Controlled Trial
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Analysis of Variance
-
Anticholesteremic Agents / pharmacology*
-
Blood Coagulation / drug effects*
-
Diabetes Mellitus, Type 2 / physiopathology*
-
Double-Blind Method
-
Fatty Acids, Monounsaturated / pharmacology*
-
Female
-
Fibrinolysis / drug effects*
-
Fluvastatin
-
Humans
-
Hyperlipidemias / drug therapy*
-
Indoles / pharmacology*
-
Lipids / blood
-
Male
-
Middle Aged
Substances
-
Anticholesteremic Agents
-
Fatty Acids, Monounsaturated
-
Indoles
-
Lipids
-
Fluvastatin